Keystone Financial Group Bristol Myers Squibb CO Transaction History

Keystone Financial Group

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$63.71 - $70.74 $1,274 - $1,414	-20 Reduced 0.6%	3,290 $210,000
Q4 2022 Feb 07, 2023	BUY	$68.48 - $81.09 $1,369 - $1,621	20 Added 0.61%	3,310 $238,000
Q3 2022 Nov 10, 2022	BUY	$0.13 - $76.84 $3 - $1,997	26 Added 0.8%	3,290 $234,000
Q1 2022 May 13, 2022	SELL	$61.48 - $73.72 $3,135 - $3,759	-51 Reduced 1.54%	3,264 $238,000
Q4 2021 Feb 11, 2022	BUY	$53.63 - $62.52 $177,783 - $207,253	3,315 New	3,315 $207,000
Q3 2021 Nov 12, 2021	SELL	$59.17 - $69.31 $196,148 - $229,762	-3,315 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$61.91 - $67.42 $681 - $741	11 Added 0.33%	3,315 $222,000
Q4 2019 Feb 06, 2020	BUY	$49.21 - $64.19 $162,589 - $212,083	3,304 New	3,304 $212,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Keystone Financial Group, based on Form 13F filings with the SEC.

Stay updated on Keystone Financial Group with notifications on news.